Drug Profile
Research programme: HLA-DQ2 blockers - Alvine Pharmaceuticals
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Alvine Pharmaceuticals
- Class Digestion aids
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coeliac disease
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Coeliac disease in USA
- 07 Aug 2017 Early research in Coeliac disease in USA before August 2017 (Alvine Pharmaceuticals pipeline, August 2017)